Bromide

Bromide

SCHEMBL1730174

Br.CCOc1cc2c(nc1C(=O)NC)C(=N)N(CC(=O)c1ccc(OCCCCC(=O)O)c(N3CCCC3)c1)C2

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADRA1D known ✓ P25100 4/20 0.32
ADRA1A known ✓ P35348 4/20 0.32
ADRA1B known ✓ P35368 4/20 0.32
HTR1A known ✓ P08908 1/20 0.32
F2R P25116 6/20 0.36
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 2/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HCAR1 Q9BXC0 1/20 0.32
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1732810 0.88 F2R (0.34) F2RMAPTALDH1A1
Bromide SCHEMBL1730497 0.87 F2R (0.48) F2R
Bromide SCHEMBL5488082 0.87 F2R (0.48) F2R
Bromide SCHEMBL1730090 0.87 F2R (0.38) F2RMAPT
Bromide SCHEMBL5482746 0.87 LMNA (0.34) F2RMAPTLMNAHPGDL3MBTL1
SCHEMBL1730143 0.86 F2R (0.48) F2R
Bromide SCHEMBL1732650 0.86 F2R (0.35) F2RMAPTLMNAALDH1A1
Bromide SCHEMBL1730166 0.86 F2R (0.39) F2RMAPTGAAADRA1DADRA1A
Bromide SCHEMBL1730006 0.86 F2R (0.49) F2R
Bromide SCHEMBL1730185 0.84 F2R (0.36) F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1391451-A1 2-IMINOPYRROLIDINE DERIVATES Eisai Co., Ltd. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 ADRA1D 31/4885ADRA1A 100/4885ADRA1B 84/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 ADRA1D 31/4885ADRA1A 102/4885ADRA1B 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.